Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Stem Cells (hMSCs and CSCs) for Ischemic Heart Failure
NCT02503280Phase 2Withdrawn
- Start
- Mar 2025
- Primary completion
- Mar 2030
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of autologous c-kit-positive cardiac stem cells in ischemic cardiomyopathy (ICM) and heart failure (HF) (3 arms). Primary endpoint: Treatment Emergent Serious Adverse Events at 1 month. Planned start Mar 2025; status: withdrawn.
02
Drugs
autologous c-kit-positive cardiac stem cells
03
Conditions
ischemic cardiomyopathy (ICM)heart failure (HF)
Beyond the preview
Go deeper on NCT02503280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02503280.